Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 13/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | RARA | P10276 | 3/20 | 0.38 |
| ▸ | RARB | P10826 | 3/20 | 0.38 |
| ▸ | RARG | P13631 | 3/20 | 0.38 |
| ▸ | RXRA | P19793 | 3/20 | 0.38 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.38 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.38 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6261746 | 1.00 | PTGS2 (0.47) | PTGS2PTGS1CYP2C9ALOX5RARA | |
| SCHEMBL6525798 | 0.88 | MAPK13 (0.48) | PTGS2CYP2C9ALOX5MAPK13MAPK12 | |
| SCHEMBL4907616 | 0.83 | PTGS2 (0.67) | PTGS2PTGS1CYP2C9RARARARB | |
| SCHEMBL4592735 | 0.76 | PTGS2 (0.53) | PTGS2PTGS1CYP2C9AOC3 | |
| SCHEMBL4593759 | 0.76 | PTGS2 (0.79) | PTGS2PTGS1CYP2C9ALOX5RARA | |
| SCHEMBL4592621 | 0.74 | PTGS2 (0.52) | PTGS2PTGS1ALOX5MAPK13MAPK12 | |
| SCHEMBL8421797 | 0.73 | PTGS2 (0.65) | PTGS2PTGS1CYP2C9ALOX5RARA | |
| SCHEMBL4593501 | 0.71 | BRAF (0.55) | ALOX5MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL8421061 | 0.71 | PTGS2 (0.88) | PTGS2PTGS1CYP2C9ALOX5RARA | |
| SCHEMBL4668470 | 0.70 | PTGS2 (0.69) | PTGS2PTGS1CYP2C9RARARARB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1545535-A4 | TREATMENT OF PAIN BY INHIBITION OF P38 MAP KINASE | SCIOS INC (US) | 2008-06-04 | — | — | EP | disclosed |
| EP-1545535-A2 | TREATMENT OF PAIN BY INHIBITION OF P38 MAP KINASE | SCIOS INC. (US) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004024083-A2 | METHODS OF BONE HEALING | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2004-03-25 | — | — | WO | disclosed |
| WO-2004021988-A2 | TREATMENT OF PAIN BY INHIBITION OF P38 MAP KINASE | SCIOS INC. (US) | 2004-03-18 | — | — | WO | disclosed |
| US-20030153569-A1 | Novel pyrazole and pyrazoline substituted compounds | SMITHKLINE BEECHAM CORPORATION | 2003-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153569-A1 | Novel pyrazole and pyrazoline substituted compounds | PDXK, COQ8A, PDK3 | PTGS2 3455/4885PTGS1 3580/4885CYP2C9 756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.